<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
IOBT
IO Biotech
$
()


  • IO Biotech reports Q4 EPS (40c), consensus (39c)

    3/5/2024 - 16:44pm
  • IO Biotech announces first patient dosed in Phase 2 trial of IO102-IO103

    12/21/2023 - 08:33am
  • IO Biotech appoints Helen Collins to board of directors

    11/13/2023 - 08:26am
  • IO Biotech reports Q3 EPS (43c), consensus (44c)

    11/13/2023 - 08:22am
  • IO Biotech completes enrollment in Phase 3 trial of advanced melanoma

    11/10/2023 - 08:13am
  • IO Biotech presents three posters at SITC meeting

    11/1/2023 - 08:43am
  • IO Biotech initiated with an Overweight at Piper Sandler

    9/28/2023 - 05:15am
  • IO Biotech announces data related to IO102-IO103 in combination with KEYTRUDA

    9/12/2023 - 08:12am
  • IO Biotech files to sell 74.13M shares of common stock for holders

    8/30/2023 - 16:21pm
  • IO Biotech reports Q2 EPS (74c), consensus (64c)

    8/11/2023 - 08:37am
  • IO Biotech appoints Hunter to board of directors

    8/11/2023 - 08:15am
  • IO Biotech to sell 37.07M shares at $2.025 in private placement

    8/7/2023 - 08:40am
  • IO Biotech announces first patient dosed in trial to evaluate IO102-IO103

    7/28/2023 - 08:08am
  • IO Biotech appoints Qasim Ahmad MD, CMO, Faulkner CTO

    7/18/2023 - 16:12pm
  • IO Biotech announces achievement of Phase 3 trial recruitment milestone

    6/14/2023 - 08:10am
dynamic_feed Breaking News